Publications by authors named "Maria-Eugenia Palacio-Lacambra"
Article Synopsis
- The study analyzed 10 years of data on adult patients with solid tumors enrolled in clinical trials, focusing on the clinical characteristics and the financial impact of sponsor contributions to drug costs.
- Over the decade, the number of clinical trials increased significantly from 140 in 2010 to 459 in 2019, with a shift in drug use from mainly targeted therapies to a greater emphasis on immunotherapy.
- The analysis showed that while the overall expenditure on antineoplastic drugs outside clinical trials was over EUR 120 million, sponsor contributions in trial settings amounted to about EUR 107 million, resulting in a potential cost avoidance of around EUR 92 million.
Aims: Accurately estimating kidney function is essential for the safe administration of renally cleared drugs such as ganciclovir. Current practice recommends adjusting renally eliminated drugs according to the Cockcroft-Gault equation. There are no data on the utility of the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations in ganciclovir dosing.
View Article and Find Full Text PDF